Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients

Abstract

'Chengyu Wang' 'Dong Wei' 'Lingzhi Shi' 'Bo Wu' 'Jinyu Chen'] We aimed to (i) develop a population pharmacokinetic model of tacrolimus in Chinese lung transplant recipients, and (ii) propose model-based dosing regimens for individualized treatment. We obtained 807 tacrolimus steady-state whole blood concentrations from 52 lung transplant patients and genotyped CYP3A53. Population pharmacokinetic analysis was performed using nonlinear mixed-effects modeling. Monte Carlo simulations were employed to determine the initial dosing regimens. Tacrolimus pharmacokinetics was described by a one-compartment model with first-order absorption and elimination processes. In CYP3A53/3 70-kg patients with 30% hematocrit and voriconazole-free therapy, the mean estimated apparent clearance was 13.1 l h -1 with 20.1% inter-subject variability, which was lower than that in Caucasian lung transplant patients (17.5–36.5 l h -1). Hematocrit, postoperative days, tacrolimus daily dose, voriconazole concomitant therapy, and CYP3A53 genotype were identified as significant covariates for tacrolimus clearance. To achieve target trough concentration (10–15 ng ml-1) on the 8 th day post-transplant, a higher initial dosage than the current regimen of 0.04 mg kg-1 every 12 hours is recommended for CYP3A51/3 patients without voriconazole concomitant therapy. Given the nonlinear kinetics of tacrolimus and large variability, population pharmacokinetic model should be combined with therapeutic drug monitoring to optimize individualized therapy.